<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="gastroenterology" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">168</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2023.30602</article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Gastroenterology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Efficacy and Safety of Antispasmodic agents in the Management of Irritable Bowel Syndrome: A Systematic Review
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ghamdi</surname>
<given-names>Khalid Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Albluwi</surname>
<given-names>Naif</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alammari</surname>
<given-names>Ali</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alibrahim</surname>
<given-names>Hassan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Thabet</surname>
<given-names>Amal</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Radhi</surname>
<given-names>Janan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alnamshah</surname>
<given-names>Fahad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alghamdi</surname>
<given-names>Khalid</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alshammari</surname>
<given-names>Nashmeah</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghalib</surname>
<given-names>Sahar</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dawood</surname>
<given-names>Abdullah Al</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>18</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>3</volume>
<issue>6</issue>
<fpage>167</fpage>
<lpage>180</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>Background: Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder with various subtypes and unclear causes. Antispasmodic agents, such as smooth muscle relaxants or anticholinergic drugs, target gut muscle contractions to relieve abdominal pain and spasms. Individualized treatment is important, considering symptoms, IBS subtype, and patient response. Combination therapy with antispasmodics, dietary adjustments, stress management, and probiotics can enhance symptom control and improve quality of life for IBS patients.
Methods: Online databases were searched for pertinent English publications that met the inclusion and exclusion criteria of this research (Cochrane library, PubMed, and web of science, respectively). Treatment response or therapeutic efficacy, global or clinical improvement, symptom reduction (abdominal pain relief, bowel motility, Bristol stool score), and adverse events (nausea, dizziness, high blood pressure) were all evaluated as clinical endpoints.
Results: Eight randomized clinical trials involving 1227 IBS patients were included. The studies were conducted between 2014 and 2020, with the majority of participants being female. The endpoints of the studies showed significant reductions in abdominal pain severity, bowel motility, ibs symptom severity, and improvements in quality of life and Bristol stool score. Adverse events were reported in all studies except one, with nausea and dizziness being the main findings. Overall, the review indicated varying degrees of effectiveness of antispasmodics in alleviating IBS symptoms.
Conclusion: In conclusion, antispasmodic agents, including mebeverine, otilonium bromide, alverine citrate/simethicone, pinaverium bromide, phloroglucinol, drotaverine hydrochloride, and peppermint oil, have shown effectiveness in relieving IBS symptoms. However, the quality and design of the studies varied, and many trials were short-term, limiting their clinical significance for a chronic condition like IBS. Further research with larger samples, longer durations, and standardized endpoints is needed to provide more conclusive evidence on the efficacy and safety of antispasmodics in managing IBS.
</p>
</abstract>
<kwd-group>
<kwd>irritable bowel syndrome</kwd>
<kwd> antispasmodic agents</kwd>
<kwd> spasmolytic</kwd>
<kwd> efficacy</kwd>
<kwd> effectiveness</kwd>
<kwd> safety</kwd>
<kwd> adverse effects</kwd>
</kwd-group>
</article-meta>
</front>
</article>